BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32122920)

  • 21. Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells.
    Peters HL; Tripathi SC; Kerros C; Katayama H; Garber HR; St John LS; Federico L; Meraz IM; Roth JA; Sepesi B; Majidi M; Ruisaard K; Clise-Dwyer K; Roszik J; Gibbons DL; Heymach JV; Swisher SG; Bernatchez C; Alatrash G; Hanash S; Molldrem JJ
    Cancer Immunol Res; 2017 Apr; 5(4):319-329. PubMed ID: 28254787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of a cancer/testis (CT) antigen gene family capable of eliciting humoral response in cancer patients.
    Parmigiani RB; Bettoni F; Vibranovski MD; Lopes MH; Martins WK; Cunha IW; Soares FA; Simpson AJ; de Souza SJ; Camargo AA
    Proc Natl Acad Sci U S A; 2006 Nov; 103(48):18066-71. PubMed ID: 17114284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer.
    Mazzaferro V; Coppa J; Carrabba MG; Rivoltini L; Schiavo M; Regalia E; Mariani L; Camerini T; Marchianò A; Andreola S; Camerini R; Corsi M; Lewis JJ; Srivastava PK; Parmiani G
    Clin Cancer Res; 2003 Aug; 9(9):3235-45. PubMed ID: 12960108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inflammation-Induced Abnormal Expression of Self-molecules on Epithelial Cells: Targets for Tumor Immunoprevention.
    Jacqueline C; Lee A; Frey N; Minden JS; Finn OJ
    Cancer Immunol Res; 2020 Aug; 8(8):1027-1038. PubMed ID: 32467324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antigen-specific vaccines for cancer treatment.
    Tagliamonte M; Petrizzo A; Tornesello ML; Buonaguro FM; Buonaguro L
    Hum Vaccin Immunother; 2014; 10(11):3332-46. PubMed ID: 25483639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor cell lysates as immunogenic sources for cancer vaccine design.
    González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F
    Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of TCR β CDR3 sequencing data for tracking anti-tumor immunity.
    Zhang J; Ji Z; Smith KN
    Methods Enzymol; 2019; 629():443-464. PubMed ID: 31727253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a novel cancer-testis antigen CRT2 frequently expressed in various cancers using representational differential analysis.
    Hayashi E; Matsuzaki Y; Hasegawa G; Yaguchi T; Kurihara S; Fujita T; Kageshita T; Sano M; Kawakami Y
    Clin Cancer Res; 2007 Nov; 13(21):6267-74. PubMed ID: 17975137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural T cell immunity against cancer.
    Nagorsen D; Scheibenbogen C; Marincola FM; Letsch A; Keilholz U
    Clin Cancer Res; 2003 Oct; 9(12):4296-303. PubMed ID: 14555498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of peptide-specific TCR genes by in vitro peptide stimulation and CDR3 length polymorphism analysis.
    Shao H; Lin Y; Wang T; Ou Y; Shen H; Tao C; Wu F; Zhang W; Bo H; Wang H; Huang S
    Cancer Lett; 2015 Jul; 363(1):83-91. PubMed ID: 25890221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.
    Salmaninejad A; Zamani MR; Pourvahedi M; Golchehre Z; Hosseini Bereshneh A; Rezaei N
    Immunol Invest; 2016 Oct; 45(7):619-40. PubMed ID: 27603913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-Cell Analysis of Target Antigens of CAR-T Reveals a Potential Landscape of "On-Target, Off-Tumor Toxicity".
    Zhang Y; Li Y; Cao W; Wang F; Xie X; Li Y; Wang X; Guo R; Jiang Z; Guo R
    Front Immunol; 2021; 12():799206. PubMed ID: 34975912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
    Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor antigen discovery through translation of the cancer genome.
    Khodadoust MS; Alizadeh AA
    Immunol Res; 2014 May; 58(2-3):292-9. PubMed ID: 24718952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mRNA Cancer Vaccines.
    Fiedler K; Lazzaro S; Lutz J; Rauch S; Heidenreich R
    Recent Results Cancer Res; 2016; 209():61-85. PubMed ID: 28101688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
    Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
    J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine.
    Shawler DL; Bartholomew RM; Garrett MA; Trauger RJ; Dorigo O; Van Beveren C; Marchese A; Ferre F; Duffy C; Carlo DJ; Sherman LA; Gold DP; Sobol RE
    Clin Exp Immunol; 2002 Jul; 129(1):99-106. PubMed ID: 12100028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients.
    Schlienger K; Chu CS; Woo EY; Rivers PM; Toll AJ; Hudson B; Maus MV; Riley JL; Choi Y; Coukos G; Kaiser LR; Rubin SC; Levine BL; Carroll RG; June CH
    Clin Cancer Res; 2003 Apr; 9(4):1517-27. PubMed ID: 12684428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma.
    Dettling S; Stamova S; Warta R; Schnölzer M; Rapp C; Rathinasamy A; Reuss D; Pocha K; Roesch S; Jungk C; Warnken U; Eckstein V; Grabe N; Schramm C; Weigand MA; von Deimling A; Unterberg A; Beckhove P; Herold-Mende C
    Clin Cancer Res; 2018 Jun; 24(12):2951-2962. PubMed ID: 29563135
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.